公开(公告)号：US20240327526A1

公开(公告)日：2024-10-03

申请号：US18381745

申请日：2023-10-19

Applicant: AMGEN INC.

Inventor： Huiquan HAN ,  Xiaolan ZHOU ,  Qing CHEN ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61K39/00 ,  A61P21/00 ,  C07K16/42 ,  C07K16/46

CPC classification number: C07K16/2863 ,  A61P21/00 ,  C07K16/42 ,  C07K16/468 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.

公开(公告)号：US20210340262A1

公开(公告)日：2021-11-04

申请号：US17205144

申请日：2021-03-18

Applicant: AMGEN INC.

Inventor： Huiquan HAN ,  Xiaolan ZHOU ,  Qing CHEN ,  Mei-Mei TSAI

IPC: C07K16/28 ,  A61P21/00 ,  C07K16/46 ,  C07K16/42

Abstract: This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.